MIF and airway hyperresponsiveness: In the present study, the use of the MIF inhibitor 4-IPP significantly reduced Th2 inflammatory factors (IL-5 and IL-13) production, respiratory resistance as well as airway remodeling in OVA-induced asthmatic rat models via ERK/Drp1 pathway and autophagy activation, showing effective drug potential to alleviate airway hyperresponsiveness and asthma progression.